vs

Side-by-side financial comparison of Forward Industries, Inc. (FWDI) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

Forward Industries, Inc. is the larger business by last-quarter revenue ($21.4M vs $19.6M, roughly 1.1× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -2732.2%, a 2554.8% gap on every dollar of revenue. On growth, Forward Industries, Inc. posted the faster year-over-year revenue change (224.0% vs -11.5%). Over the past eight quarters, Forward Industries, Inc.'s revenue compounded faster (74.6% CAGR vs -12.2%).

Melrose Industries plc is a British aerospace manufacturing company based in Birmingham, England. It is the parent company of GKN Aerospace. The company's shares are listed on the London Stock Exchange as a constituent of the FTSE 100 Index.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

FWDI vs LAB — Head-to-Head

Bigger by revenue
FWDI
FWDI
1.1× larger
FWDI
$21.4M
$19.6M
LAB
Growing faster (revenue YoY)
FWDI
FWDI
+235.5% gap
FWDI
224.0%
-11.5%
LAB
Higher net margin
LAB
LAB
2554.8% more per $
LAB
-177.4%
-2732.2%
FWDI
Faster 2-yr revenue CAGR
FWDI
FWDI
Annualised
FWDI
74.6%
-12.2%
LAB

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
FWDI
FWDI
LAB
LAB
Revenue
$21.4M
$19.6M
Net Profit
$-585.7M
$-34.7M
Gross Margin
78.6%
48.5%
Operating Margin
-2722.8%
-168.5%
Net Margin
-2732.2%
-177.4%
Revenue YoY
224.0%
-11.5%
Net Profit YoY
-82611.5%
-28.8%
EPS (diluted)
$-5.91
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FWDI
FWDI
LAB
LAB
Q4 25
$21.4M
Q3 25
$7.9M
$19.6M
Q2 25
$2.5M
$21.8M
Q1 25
$3.1M
$40.8M
Q4 24
$6.6M
Q3 24
$22.1M
Q2 24
$7.8M
$22.5M
Q1 24
$5.1M
$45.5M
Net Profit
FWDI
FWDI
LAB
LAB
Q4 25
$-585.7M
Q3 25
$-164.0M
$-34.7M
Q2 25
$-850.0K
$-33.5M
Q1 25
$-1.5M
$-26.0M
Q4 24
$-708.1K
Q3 24
$-26.9M
Q2 24
$-399.6K
$-45.7M
Q1 24
$-553.2K
$-32.2M
Gross Margin
FWDI
FWDI
LAB
LAB
Q4 25
78.6%
Q3 25
61.1%
48.5%
Q2 25
48.8%
Q1 25
-5.7%
48.4%
Q4 24
17.1%
Q3 24
54.9%
Q2 24
16.8%
46.1%
Q1 24
26.2%
53.1%
Operating Margin
FWDI
FWDI
LAB
LAB
Q4 25
-2722.8%
Q3 25
-39.2%
-168.5%
Q2 25
-102.6%
-118.1%
Q1 25
-58.3%
-80.8%
Q4 24
-13.6%
Q3 24
-120.9%
Q2 24
-5.9%
-134.5%
Q1 24
-12.2%
-132.2%
Net Margin
FWDI
FWDI
LAB
LAB
Q4 25
-2732.2%
Q3 25
-2063.6%
-177.4%
Q2 25
-34.1%
-153.7%
Q1 25
-46.5%
-63.8%
Q4 24
-10.7%
Q3 24
-122.0%
Q2 24
-5.1%
-203.3%
Q1 24
-10.9%
-70.6%
EPS (diluted)
FWDI
FWDI
LAB
LAB
Q4 25
$-5.91
Q3 25
$-21.86
$-0.09
Q2 25
$-0.77
$-0.09
Q1 25
$-1.32
$-0.07
Q4 24
$-0.64
Q3 24
$-0.07
Q2 24
$-0.36
$-0.12
Q1 24
$-0.50
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FWDI
FWDI
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$880.9M
$399.7M
Total Assets
$892.9M
$539.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FWDI
FWDI
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
FWDI
FWDI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
FWDI
FWDI
LAB
LAB
Q4 25
$880.9M
Q3 25
$1.5B
$399.7M
Q2 25
$3.4M
$424.5M
Q1 25
$3.6M
$454.6M
Q4 24
$2.3M
Q3 24
$489.3M
Q2 24
$1.4M
$510.3M
Q1 24
$1.8M
$577.3M
Total Assets
FWDI
FWDI
LAB
LAB
Q4 25
$892.9M
Q3 25
$1.5B
$539.6M
Q2 25
$8.3M
$557.0M
Q1 25
$12.3M
$579.6M
Q4 24
Q3 24
$681.5M
Q2 24
$15.2M
$708.7M
Q1 24
$15.2M
$777.7M
Debt / Equity
FWDI
FWDI
LAB
LAB
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FWDI
FWDI
LAB
LAB
Operating Cash FlowLast quarter
$-7.9M
$-22.2M
Free Cash FlowOCF − Capex
$-23.1M
FCF MarginFCF / Revenue
-118.1%
Capex IntensityCapex / Revenue
0.0%
4.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FWDI
FWDI
LAB
LAB
Q4 25
$-7.9M
Q3 25
$-4.5M
$-22.2M
Q2 25
$-1.2M
$-20.7M
Q1 25
$-537.6K
$-30.3M
Q4 24
$-434.3K
Q3 24
$-27.9M
Q2 24
$436.0K
$-39.0M
Q1 24
$-62.5M
Free Cash Flow
FWDI
FWDI
LAB
LAB
Q4 25
Q3 25
$-4.5M
$-23.1M
Q2 25
$-1.2M
$-22.6M
Q1 25
$-539.0K
$-35.3M
Q4 24
$-439.7K
Q3 24
$-30.1M
Q2 24
$426.8K
$-41.0M
Q1 24
$-63.3M
FCF Margin
FWDI
FWDI
LAB
LAB
Q4 25
Q3 25
-57.0%
-118.1%
Q2 25
-50.0%
-103.6%
Q1 25
-17.3%
-86.6%
Q4 24
-6.6%
Q3 24
-136.4%
Q2 24
5.5%
-182.2%
Q1 24
-138.9%
Capex Intensity
FWDI
FWDI
LAB
LAB
Q4 25
0.0%
Q3 25
0.3%
4.5%
Q2 25
0.8%
8.7%
Q1 25
0.0%
12.4%
Q4 24
0.1%
Q3 24
10.2%
Q2 24
0.1%
8.6%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FWDI
FWDI

CODM$17.4M81%
Design Segment$4.1M19%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons